Travere Therapeutics, Inc. Quarterly Operating Income (Loss) in USD from Q1 2012 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Travere Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2012 to Q2 2024.
  • Travere Therapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$67.7M, a 34.9% increase year-over-year.
  • Travere Therapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$394M, a 6.24% decline year-over-year.
  • Travere Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$388M, a 21.4% decline from 2022.
  • Travere Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$320M, a 60.4% decline from 2021.
  • Travere Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$199M, a 13.2% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 -$394M -$67.7M +$36.2M +34.9% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 -$430M -$139M -$41.9M -43% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-06
Q4 2023 -$388M -$94.2M -$7.53M -8.69% Oct 1, 2023 Dec 31, 2023 10-K 2024-02-20
Q3 2023 -$381M -$92.6M -$9.98M -12.1% Jul 1, 2023 Sep 30, 2023 10-K 2024-02-20
Q2 2023 -$371M -$104M -$25.4M -32.4% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$345M -$97.4M -$25.4M -35.3% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 -$320M -$86.7M -$1.85M -2.18% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-20
Q3 2022 -$318M -$82.6M -$50.9M -160% Jul 1, 2022 Sep 30, 2022 10-K 2024-02-20
Q2 2022 -$267M -$78.5M -$43.2M -122% Apr 1, 2022 Jun 30, 2022 10-K 2024-02-20
Q1 2022 -$224M -$72M -$24.4M -51.4% Jan 1, 2022 Mar 31, 2022 10-K 2024-02-20
Q4 2021 -$199M -$84.9M +$33.7M +28.4% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-20
Q3 2021 -$233M -$31.7M -$12.3M -63.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-27
Q2 2021 -$221M -$35.3M -$12.2M -52.8% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$209M -$47.5M -$32.5M -216% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q4 2020 -$176M -$119M -$90.4M -321% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-01
Q3 2020 -$85.8M -$19.4M +$15M +43.6% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 -$101M -$23.1M +$13.4M +36.7% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-29
Q1 2020 -$114M -$15.1M +$23.2M +60.6% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$137M -$28.2M -$23.2M -465% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-01
Q3 2019 -$114M -$34.4M +$1.15M +3.22% Jul 1, 2019 Sep 30, 2019 10-K 2021-03-01
Q2 2019 -$115M -$36.5M -$15M -69.4% Apr 1, 2019 Jun 30, 2019 10-K 2021-03-01
Q1 2019 -$100M -$38.2M -$20.3M -113% Jan 1, 2019 Mar 31, 2019 10-K 2021-03-01
Q4 2018 -$80M -$4.99M +$10.2M +67.2% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-24
Q3 2018 -$90.2M -$35.6M -$25M -235% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-24
Q2 2018 -$65.3M -$21.6M -$7.96M -58.6% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-24
Q1 2018 -$57.3M -$17.9M -$3.5M -24.3% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-24
Q4 2017 -$53.8M -$15.2M +$3.05M +16.7% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 -$56.8M -$10.6M +$9.76M +47.9% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-26
Q2 2017 -$66.6M -$13.6M -$2.22M -19.5% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-26
Q1 2017 -$64.4M -$14.4M -$6.17M -74.8% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-26
Q4 2016 -$58.2M -$18.2M -$3.02M -19.9% Oct 1, 2016 Dec 31, 2016 10-K/A 2018-07-06
Q3 2016 -$55.2M -$20.4M +$124K +0.61% Jul 1, 2016 Sep 30, 2016 10-K/A 2018-07-06
Q2 2016 -$55.3M -$11.4M -$4.44M -63.9% Apr 1, 2016 Jun 30, 2016 10-K/A 2018-07-06
Q1 2016 -$50.9M -$8.24M -$137K -1.69% Jan 1, 2016 Mar 31, 2016 10-K/A 2018-07-06
Q4 2015 -$50.7M -$15.2M +$3.49M +18.7% Oct 1, 2015 Dec 31, 2015 10-K 2017-03-01
Q3 2015 -$54.2M -$20.5M +$1.37M +6.27% Jul 1, 2015 Sep 30, 2015 10-K 2017-03-01
Q2 2015 -$55.6M -$6.94M +$10.2M +59.6% Apr 1, 2015 Jun 30, 2015 10-K 2017-03-01
Q1 2015 -$65.9M -$8.1M +$14M +63.3% Jan 1, 2015 Mar 31, 2015 10-K 2017-03-01
Q4 2014 -$79.8M -$18.7M -$6.82M -57.5% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-26
Q3 2014 -$73M -$21.9M -$15.8M -263% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-26
Q2 2014 -$57.1M -$17.2M -$12.2M -245% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-26
Q1 2014 -$44.9M -$22.1M -$20.2M -1070% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-26
Q4 2013 -$24.8M -$11.9M +$1.63M +12.1% Oct 2, 2013 Dec 31, 2013 10-K 2015-03-11
Q3 2013 -$26.4M -$6.03M +$2.43M +28.7% Jul 1, 2013 Sep 30, 2013 10-Q/A 2015-07-09
Q2 2013 -$28.8M -$4.98M -$245K -5.17% Apr 1, 2013 Jun 30, 2013 10-K 2015-03-11
Q1 2013 -$28.6M -$1.89M +$1.67M +47% Jan 1, 2013 Mar 31, 2013 10-K 2015-03-11
Q4 2012 -$30.3M -$13.5M Oct 1, 2012 Dec 31, 2012 10-K/A 2015-07-09
Q3 2012 -$8.46M Jul 1, 2012 Sep 30, 2012 10-Q/A 2015-07-09
Q2 2012 -$4.74M Apr 1, 2012 Jun 30, 2012 10-Q 2013-09-16
Q1 2012 -$3.56M Jan 1, 2012 Mar 31, 2012 10-Q/A 2013-09-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.